{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:41:11Z","timestamp":1787312471940,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"FoU funding from Stockholm Region"},{"DOI":"10.13039\/501100003186","name":"Fredrik och Ingrid Thurings Stiftelse","doi-asserted-by":"publisher","award":["2022-00721"],"award-info":[{"award-number":["2022-00721"]}],"id":[{"id":"10.13039\/501100003186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Most individuals diagnosed with borderline personality disorder (BPD) use psychotropic medications. BPD symptom severity is elevated in young adulthood, but medication utilisation studies in young adults with BPD are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To investigate the use of central nervous system (CNS) acting medications among young adults (aged 18\u201324), who were diagnosed with BPD, focusing on the years around the first established diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cohort study of all individuals with a registered BPD diagnosis in Sweden was conducted using national population register data. Dispensed prescriptions between July 2005 and June 2020 were utilised. Prevalent use, long-term use, and co-medication were investigated during specific 1-year periods: the year before, and then the first, second, and third year after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Medication use peaked for all three measures in the year following the first BPD diagnosis: 90.3% used CNS-acting medication during that year, and antidepressants were the most used group (70.1%). Furthermore, 74.5% used medication for &gt;12\u2009months, and 34.8% used \u2a7e3 medication groups in co-medication. Compared to a reference group of individuals diagnosed with depression, the BPD group used more medication. In the depression group, 87.5% used medication, 55.2% used medication for &gt;12\u2009months, and 3.8% used \u2a7e3 medication groups in co-medication. Moreover, medication use increased from 2006 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This indicates the importance of continuously evaluating risks and benefits with medication use, and in having easy access to up-to-date guidance about best clinical practice for individuals diagnosed with BPD, to facilitate appropriate and safe medication use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251413479","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:33:33Z","timestamp":1771238013000},"page":"1343-1351","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Central nervous system acting medication used by young adults with borderline personality disorder in Sweden 2006\u20132019"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6435-0817","authenticated-orcid":false,"given":"Annika","family":"Tiger","sequence":"first","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet &amp; Stockholm Health Care Services, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Molero","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet &amp; Stockholm Health Care Services, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Brikell","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Biomedicine, Aarhus University, Denmark"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"School of Medical Sciences, \u00d6rebro University, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Psychological and Brain Sciences, Indiana University, Bloomington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hellner","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet &amp; Stockholm Health Care Services, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyra","family":"Lagerberg","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Psychiatry, Warneford Hospital, University of Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Jayaram-Lindstr\u00f6m","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet &amp; Stockholm Health Care Services, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579409990186"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta22170"},{"key":"e_1_3_3_4_1","volume-title":"Personlighetssyndrom : kliniska riktlinjer f\u00f6r utredning och behandling [Personality disorders: Clinical guidelines for assessment and treatment]","author":"Ekselius L","year":"2017","unstructured":"Ekselius L (2017) Personlighetssyndrom : kliniska riktlinjer f\u00f6r utredning och behandling [Personality disorders: Clinical guidelines for assessment and treatment]. Svenska psykiatriska f\u00f6reningen."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00855-4"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109046"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13094"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.24181010"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13166"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203241"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-016-0117-y"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13414"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain-2018-0307"},{"key":"e_1_3_3_15_1","unstructured":"National Board of Health and Welfare (2023) Diagnostik och l\u00e4kemedelsbehandling vid adhd F\u00f6rekomst trend och k\u00f6nsskillnader."},{"key":"e_1_3_3_16_1","volume-title":"Borderline Personality Disorder: Treatment and Management","author":"National Collaborating Centre for Mental Health","year":"2009","unstructured":"National Collaborating Centre for Mental Health (2009) National Institute for Health and Clinical Excellence: Guidance. Borderline Personality Disorder: Treatment and Management. British Psychological Society Copyright \u00a9 2009, The British Psychological Society & The Royal College of Psychiatrists."},{"key":"e_1_3_3_17_1","volume-title":"Clinical practice guideline for the management of borderline personality disorder","author":"National Health and Medical Research Council","year":"2012","unstructured":"National Health and Medical Research Council (2012) Clinical practice guideline for the management of borderline personality disorder. National Health and Medical Research Council."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116642903"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00852-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09228"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3130843"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40479-019-0106-3"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0442-0"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01161-7"},{"issue":"11","key":"e_1_3_3_25_1","article-title":"Pharmacological interventions for people with borderline personality disorder","volume":"11","author":"Stoffers-Winterling JM","year":"2022","unstructured":"Stoffers-Winterling JM, Storeb\u00f8 OJ, Pereira Ribeiro J, et al. (2022a) Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 11(11): Cd012956.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S342257"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005653.pub2"},{"issue":"5","key":"e_1_3_3_28_1","article-title":"Psychological therapies for people with borderline personality disorder","volume":"5","author":"Storeb\u00f8 OJ","year":"2020","unstructured":"Storeb\u00f8 OJ, Stoffers-Winterling JM, V\u00f6llm BA, et al. (2020) Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 5(5): Cd012955.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_29_1","author":"Swedish Medical Agency","year":"2020","unstructured":"Swedish Medical Agency (2020) F\u00f6rskrivning av opioider i Sverige: L\u00e4kemedel, doser och diagnoser [Prescription of opioids in Sweden: Drugs, doses and diagnoses].","journal-title":"F\u00f6rskrivning av opioider i Sverige: L\u00e4kemedel, doser och diagnoser"},{"key":"e_1_3_3_30_1","author":"Swedish Medical Agency","year":"2021","unstructured":"Swedish Medical Agency (2021) Utvidga kunskapen om lugnande medel och s\u00f6mnmede. [Expand the knowledge on anxiolytic-, hypnotic- and sedative agents.].","journal-title":"Utvidga kunskapen om lugnande medel och s\u00f6mnmede"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01503-z"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9450.2009.00788.x"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-1040-1"},{"key":"e_1_3_3_34_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2024) Guidelines for ATC classification and DDD assignment 2025."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2019.166"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000232"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12004"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251413479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251413479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251413479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:27:36Z","timestamp":1787182056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251413479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/02698811251413479"],"URL":"https:\/\/doi.org\/10.1177\/02698811251413479","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}